论文部分内容阅读
本文根据 WHO的骨质疏松诊断标准 ,利用双能 X射线骨密度仪 ,对 2 50例绝经后妇女做骨密度检查 ,筛选出临床诊断为原发性骨质疏松症和骨量减少的妇女 131例 ,在筛选过程中 ,确定肝肾功能正常 ,排除风湿病、肾病、甲旁亢、甲亢、胃癌及胃炎、卵巢摘除等继发性骨质疏松的妇女 ,采用随机双盲对照实验 ,分成 3组 :补肾中药组、依普拉封组、对照组 ,目的是观察补肾中药对原发性骨质疏松症和骨量减少的效果和作用机制 ,并与治疗骨质疏松的西药依普拉封做对照。方法是采用放射免疫分析的方法 ,观察被确定为原发性骨质疏松症和骨量减少的妇女治疗前后血清中卵泡生成素 (FSH)、黄体生成素(LH)、雌二醇 (E2 )的变化 ,同时观察治疗前后的骨密度 (BMD)的变化。结果发现 :补肾中药能明显提高雌激素的水平和增加骨密度 ,与西药相比无任何毒副反应 ,而依普拉封则有不同程度的副反应 (如 :反酸等胃部不适、潮热等 ) ,说明补肾中药是通过整体调节 ,提高体内的雌激素水平 ,提高骨密度 ,其疗效优于西药治疗和雌激素替代治疗的效果。
According to WHO diagnostic criteria for osteoporosis, bone mineral density (BMD) tests were performed on 250 men with postmenopausal women using dual energy X-ray absorptiometry to screen 131 women with clinically diagnosed primary osteoporosis and osteopenia Cases, in the screening process, to determine the normal liver and kidney function, excluding rheumatism, kidney disease, hyperparathyroidism, hyperthyroidism, gastric cancer and gastritis, ovariectomy and other secondary osteoporosis women, a randomized double-blind control experiment, divided into 3 Group: Bushen Chinese medicine group, Epigallocate group, control group, the purpose is to observe the effect and mechanism of Bushen Chinese medicine on primary osteoporosis and osteopenia, and with the treatment of osteoporosis western medicine Pula seal Make a comparison. The method is to use radioimmunoassay to observe the changes of serum FSH, LH, estradiol (E2) in women with primary osteoporosis and osteopenia before and after treatment, Changes in bone mineral density (BMD) before and after treatment were observed. The results showed that: kidney medicine can significantly increase the level of estrogen and increase bone mineral density, compared with Western medicine without any side effects, and according to Pulandian have varying degrees of side effects (such as: acid and other stomach upset, tide Heat, etc.), indicating that kidney medicine is through the overall regulation, increase estrogen levels in the body and increase bone mineral density, its efficacy is superior to western medicine and estrogen replacement therapy effect.